CVKD stock forecast, quote, news & analysis
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions... Show more
Cadrenal Therapeutics (CVKD) Stock Analysis: A Late-Stage Anticoagulation Pipeline at a Crossroads
Key Takeaways
- CVKD shares traded near $0.99 in late October 2026, up roughly 1.5% over the trailing 30 days—a relatively flat period despite persistent day-to-day volatility.
- Cadrenal Therapeutics is a micro-cap, late-stage biopharmaceutical company focused on under-served anticoagulation and immune-mediated thrombotic conditions.
- Its pipeline centers on tecarfarin (Phase 3-ready), CAD-1005 (a Phase 2-complete 12-LOX inhibitor for heparin-induced thrombocytopenia), and frunexian (a Phase 1-complete Factor XIa inhibitor).
- With no product revenue and a limited cash position, financing and clinical-development runway remain central concerns for investors.
- The stock trades far below its 52-week high, reflecting the broader de-rating of speculative micro-cap biotechnology names.
- For additional detail, explore the company's Price Targets, Earnings, and Forecast pages.
- You can also discover related automated strategies on the Trending AI Robots page.
Current Market Snapshot
Cadrenal Therapeutics (CVKD) is a thinly traded micro-cap that has experienced substantial price swings over the past year. After trading well above $10 at points during 2025 and early 2026, the shares have declined sharply and now change hands below $1, with a market capitalization measured in the low single-digit millions of dollars. Over the trailing 30-day window, the stock has been comparatively rangebound, hovering between roughly $0.82 and $1.10, with the latest close near $0.99.
This kind of elevated volatility is characteristic of clinical-stage biotech companies that generate no product revenue and depend heavily on financing markets and binary clinical milestones. The broader small-cap and speculative biotech environment has also contributed to a more cautious tone, pressuring valuations across the sector even as the company advances its pipeline.
Cadrenal Therapeutics (CVKD) Business Overview and Competitive Position
Cadrenal Therapeutics is a late-stage biopharmaceutical company headquartered in Ponte Vedra, Florida, developing novel therapies for life-threatening immune and thrombotic conditions. The company has built a portfolio spanning three scientific pillars, each targeting areas where standard anticoagulation has notable limitations.
Its most advanced asset, tecarfarin, is an oral vitamin K antagonist designed to provide more predictable anticoagulation than warfarin, particularly for patients with end-stage kidney disease, atrial fibrillation, or left-ventricular assist devices. Cadrenal holds a collaboration agreement with Abbott Global Enterprises to evaluate tecarfarin in LVAD patients. The pipeline also includes CAD-1005, a first-in-class selective 12-LOX inhibitor in development for heparin-induced thrombocytopenia (HIT), a serious immune-mediated clotting disorder, as well as frunexian, an intravenous Factor XIa inhibitor aimed at acute hospital settings.
Because the company has no marketed products and only a small number of employees, its investment thesis is driven primarily by clinical data, regulatory progress, and the potential addressable markets in anticoagulation rather than current fundamentals.
Recent Developments Driving CVKD
Over the past month, CVKD has been shaped less by a single discrete catalyst and more by a mix of ongoing financing considerations, clinical-stage execution, and broader sector sentiment. As a pre-revenue biotechnology company with a limited cash balance, Cadrenal's share price remains sensitive to investor perceptions of its funding runway and its ability to advance multiple programs concurrently.
The company continues to highlight its differentiated approach to anticoagulation, focusing on patient populations that are often poorly served by existing therapies, including dialysis-dependent patients and those with rare thrombotic conditions. Regulatory designations previously granted to its assets, such as orphan drug and fast track status for certain indications, remain part of the company's strategic narrative, though investors are closely watching whether these programs translate into near-term clinical milestones.
Absent major new announcements during the trailing 30-day period, trading has been largely technical, with the stock consolidating after a steep multi-month decline. Micro-cap names of this size are also especially prone to amplified moves on modest trading volume, which can exaggerate short-term price swings in either direction.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that collectively track thousands of tickers, but only the top-performing and most relevant strategies are surfaced in the curated Trending AI Robots section. These bots differ in approach, timeframe, and performance metrics, giving traders a range of options to evaluate based on their own objectives and risk tolerance. For investors monitoring volatile micro-cap names such as CVKD, the section can serve as a useful reference for identifying automated strategies that are currently gaining traction. Browsing the available robots may help you discover tools aligned with your trading style.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important factors for CVKD will center on clinical execution and balance-sheet strength. Investors are likely to monitor progress across tecarfarin, CAD-1005, and frunexian, including any updates on trial enrollment, data readouts, or regulatory interactions, as these represent the primary long-term value drivers for the company.
Financing will remain a key variable. A pre-revenue biotech with a modest cash position may need to raise additional capital to fund ongoing development, and the terms of any future financing could influence the share count and, in turn, the stock price. Macroeconomic conditions affecting risk appetite for speculative small-cap equities will also play a role, as will any sector-wide shifts in investor sentiment toward clinical-stage biotechnology.
Finally, earnings and quarterly disclosures—with the next report expected around late December 2026—will provide updated detail on spending, cash reserves, and pipeline timelines. These are informational milestones to watch rather than guarantees of direction, and they do not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CVKD in upward trend: price rose above 50-day moving average on November 03, 2026
CVKD moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 46 cases where CVKD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CVKD as a result. In 51 of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +14.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CVKD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.985) is normal, around the industry mean (3.051). P/E Ratio (-0.232) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CVKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology